Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773013 | 0.95 | ACACB (0.42) | TSHRLMNAHTR2APKMNPSR1 | |
| SCHEMBL19654590 | 0.93 | LMNA (0.53) | TSHRLMNAPKMALDH1A1USP2 | |
| SCHEMBL17767827 | 0.88 | TSHR (0.48) | TSHRLMNAHTR2APKMALDH1A1 | |
| SCHEMBL17767833 | 0.87 | LMNA (0.48) | TSHRLMNAHTR2APKMALDH1A1 | |
| SCHEMBL17767825 | 0.82 | PKM (0.62) | TSHRLMNAPKMALDH1A1ALOX15 | |
| SCHEMBL28485631 | 0.81 | HRH1 (0.38) | TSHRLMNAUSP2ALOX15CHRM4 | |
| SCHEMBL17767824 | 0.81 | LMNA (0.55) | TSHRLMNAPKMALDH1A1POLB | |
| SCHEMBL17767822 | 0.80 | ACACB (0.44) | PKMACACBPIK3CAFFAR1 | |
| SCHEMBL17767837 | 0.79 | PIK3CA (0.42) | TSHRLMNAHTR2APKMALDH1A1 | |
| SCHEMBL19640426 | 0.78 | FFAR1 (0.44) | ACACBPIK3CAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428730-B | 1,3, 5-triazinyl PI3K inhibitors as anti-cancer agents and methods of making the same | 科学与工业研究会 | 2020-10-16 | — | — | CN | claimed |
| EP-3221307-B1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-07-24 | — | — | EP | claimed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | claimed |
| CN-107428730-B | 1,3, 5-triazinyl PI3K inhibitors as anti-cancer agents and methods of making the same | 科学与工业研究会 | 2020-10-16 | — | — | CN | disclosed |
| EP-3221307-B1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-07-24 | — | — | EP | disclosed |
| EP-3221307-B1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-07-24 | — | — | EP | disclosed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | disclosed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | TSHR 3113/4885LMNA 4161/4885HTR2A 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.